A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
NCT03703908
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
5
Enrollment
INDUSTRY
Sponsor class
Stopped
Program not advancing
Conditions
Focal Segmental Glomerulosclerosis
Interventions
DRUG:
CCX140-B
Sponsor
Amgen